TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27818472

Group type: EXPERIMENTAL
Intervention: NMES with muscle contraction
Number of subjects: 34

Group type: COMPARATOR
Intervention: NMES without muscle contraction (control group)
Number of subjects: 34
Study: 25056227

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate nasal spray (FFNS) 55μg, once daily for two weeks
Number of subjects: 261

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 261
Study: 22774604

Group type: EXPERIMENTAL
Intervention: Anhydrous alcohol sclerotherapy following transrectal ultrasound-guided puncture
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cystic fluid aspiration only
Number of subjects: 44
Study: 20042423

Group type: EXPERIMENTAL
Intervention: Home‐based telemonitored cardiac rehabilitation (HTCR)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Outpatient‐based standard cardiac rehabilitation (SCR)
Number of subjects: 152
Study: 18926076

Group type: EXPERIMENTAL
Intervention: Recruitment Maneuver (RM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 15751094

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate (CS) 800 mg once daily for 2 years
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 12005122

Group type: EXPERIMENTAL
Intervention: New portable device (Model H4300 NIKKISO‐YSI CO., LTD.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional method (DermaLab, Cortex Technology)
Number of subjects: 0
Study: 9769027

Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF) 300 mg t.i.d. for 12 weeks
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Propentofylline (PPF) for 12 weeks
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study: 8556421

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0
Study: 2677423

Group type: COMPARATOR
Intervention: Various active treatments for non-small-cell lung cancer
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Various active treatments for small-cell lung cancer
Number of subjects: 150
Study: 329743

Group type: EXPERIMENTAL
Intervention: 10 mg of mianserin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 25 mg of amitriptyline
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: mianserin + alcohol (0.5 g/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: amitriptyline + alcohol (0.5 g/kg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30559073

Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cetuximab plus capecitabine
Number of subjects: 24
Study: 28003574

Group type: EXPERIMENTAL
Intervention: Combined sodium bicarbonate + ascorbic acid
Number of subjects: 429

Group type: COMPARATOR
Intervention: Saline hydration
Number of subjects: 429
Study: 26460474

Group type: EXPERIMENTAL
Intervention: Size Matters handwriting program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard instruction
Number of subjects: 0
Study: 22688603

Group type: EXPERIMENTAL
Intervention: Booklet of metaphors and stories conveying key pain biology concepts
Number of subjects: 79

Group type: COMPARATOR
Intervention: Booklet containing advice on how to manage chronic pain according to established cognitive‐behavioral principles
Number of subjects: 79
Study: 21658526

Group type: EXPERIMENTAL
Intervention: DVD-based self-help program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 24
Study: 19332424

Group type: EXPERIMENTAL
Intervention: Cognitive intervention (memory rehabilitation group)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Waitlist (control group)
Number of subjects: 52
Study: 16923322

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 42

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 42
Study: 15041108

Group type: COMPARATOR
Intervention: Sextant biopsy regimen
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: 10-core biopsy strategy
Number of subjects: 405

Group type: EXPERIMENTAL
Intervention: Re-biopsy including t-zone sampling
Number of subjects: 405
Study: 11368985

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 80

Group type: COMPARATOR
Intervention: Norplant
Number of subjects: 80
Study: 9205765

Group type: EXPERIMENTAL
Intervention: ebrotidine 800 mg
Number of subjects: 50

Group type: COMPARATOR
Intervention: ranitidine 300 mg
Number of subjects: 50
Study: 7708637

Group type: EXPERIMENTAL
Intervention: Intramuscular isoniazid, pyrazinamide+rifampicin
Number of subjects: 265

Group type: EXPERIMENTAL
Intervention: Long-term treatment (12 months and more) with all tuberculostatic agents and surgical intervention
Number of subjects: 265
Study: 3308720

Group type: EXPERIMENTAL
Intervention: Ceftazidime (80‐100 mg/kg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Netilmicin (6 mg/kg/day)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (20 subjects)
Number of subjects: 40
Study: 28714658

Group type: EXPERIMENTAL
Intervention: Progressive shoulder-neck exercise program (6 weeks)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Traditional physiotherapy
Number of subjects: 72
Study: 27881145

Group type: EXPERIMENTAL
Intervention: Pragmatic intervention by a social worker to support informal caregivers
Number of subjects: 0
Study: 24633406

Group type: EXPERIMENTAL
Intervention: Gradual tapering of clopidogrel maintenance therapy over four weeks
Number of subjects: 782

Group type: COMPARATOR
Intervention: Abrupt discontinuation of clopidogrel therapy after continued therapy for an additional four weeks
Number of subjects: 782

Group type: EXPERIMENTAL
Intervention: Gradual tapering of clopidogrel maintenance therapy
Number of subjects: 782

Group type: COMPARATOR
Intervention: Abrupt discontinuation of clopidogrel therapy
Number of subjects: 782
Study: 23732173

Group type: EXPERIMENTAL
Intervention: Goal-directed hemodynamic therapy guided by stroke volume variation, optimized global end-diastolic volume index, mean arterial pressure, and cardiac index (SG)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Algorithm based on mean arterial pressure and central venous pressure (CG)
Number of subjects: 100
Study: 19969446

Group type: EXPERIMENTAL
Intervention: Tiotropium via Respimat (5microg)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Tiotropium via HandiHaler (18microg)
Number of subjects: 134
Study: 18808445

Group type: EXPERIMENTAL
Intervention: Naloxone-3-glucuronide (NX3G) 0.16 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Morphine 0.05 mg/kg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 16192723

Group type: EXPERIMENTAL
Intervention: Donepezil 5 mg/day
Number of subjects: 1219

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 1219
Study: 14516877

Group type: EXPERIMENTAL
Intervention: trapidil 100 mg 3 times daily
Number of subjects: 1743

Group type: COMPARATOR
Intervention: Control (no trapidil)
Number of subjects: 1743
Study: 10232717

Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1))
Number of subjects: 15

Group type: COMPARATOR
Intervention: Etomidate (0.3 mg x kg(‐1))
Number of subjects: 15
Study: 8912772

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nocturnal asthma (NA) at 4:00 A.M.
Number of subjects: 21

Group type: COMPARATOR
Intervention: Alveolar tissue eosinophils
Number of subjects: 21
Study: 1748136

Group type: EXPERIMENTAL
Intervention: Nifedipine 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nifedipine 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol 100 mg
Number of subjects: 12
Study: 6805361

Group type: COMPARATOR
Intervention: 0 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 2 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 mg morphine in 1 ml saline + 6 ml bupivacaine 0.5%
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 4 mg morphine in 6 ml saline
Number of subjects: 80
Study: 31067138

Group type: EXPERIMENTAL
Intervention: Local Consolidative Therapy (LCT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Maintenance Therapy or Observation (MT/O)
Number of subjects: 49
Study: 28849623

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) iron sucrose
Number of subjects: 192

Group type: COMPARATOR
Intervention: Oral ferrous sulfate
Number of subjects: 192
Study: 27892820

Group type: EXPERIMENTAL
Intervention: Peer-led educational programme 'Listen Up'
Number of subjects: 7709

Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 7709
Study: 24717794

Group type: EXPERIMENTAL
Intervention: TAA‐AQ (triamcinolone acetonide aqueous nasal spray, 110 μg for 2-11 years old or 220 μg for 6-11 years old)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: TAA‐AQ (triamcinolone acetonide aqueous nasal spray)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 22266992

Group type: EXPERIMENTAL
Intervention: High Concentrate/High Gain (HC/HG) diet
Number of subjects: 12

Group type: COMPARATOR
Intervention: High Forage/Low Gain (HF/LG) diet
Number of subjects: 12
Study: 18996033

Group type: EXPERIMENTAL
Intervention: 1.7 mL of 4% articaine/HCl injected into the buccal vestibule
Number of subjects: 71

Group type: COMPARATOR
Intervention: Routine administration with additional palatal injection
Number of subjects: 71
Study: 17617286

Group type: EXPERIMENTAL
Intervention: C.E.R.A. administered at one of three doses (0.25 pg/150 IU, 0.4 pg/150 IU, or 0.6 pg/150 IU) with frequency subgroups of QW or Q2W.
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: C.E.R.A. QW or Q2W
Number of subjects: 91
Study: 15359376

Group type: EXPERIMENTAL
Intervention: Clomethiazole (1st day: 3 x 384 mg, 2nd day: 4 x 384 mg, 3rd day: 3 x 384 mg, 4th day: 2 x 384 mg, 5th day: 1 x 384 mg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 11574936

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training with vaginal balls
Number of subjects: 37

Group type: COMPARATOR
Intervention: Pelvic floor muscle training without vaginal balls
Number of subjects: 37
Study: 9609408

Group type: EXPERIMENTAL
Intervention: Acute normovolaemic haemodilution (group 1) with 500 ml of blood withdrawn and 6% hydroxyethyl starch infused
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (group 2) without haemodilution and autologous blood transfusion
Number of subjects: 16
Study: 7820060

Group type: EXPERIMENTAL
Intervention: Interferon alfa-2b (IFN)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Pentostatin
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 2-chlorodeoxyadenosine (2-CdA)
Number of subjects: 69
Study: 3403476

Group type: EXPERIMENTAL
Intervention: 0.45 g NaCl per 100 ml water (Na-R)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Tap water (H2O-R)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Na-R
Number of subjects: 6

Group type: COMPARATOR
Intervention: H2O-R
Number of subjects: 6
Study: 2050460

Group type: EXPERIMENTAL
Intervention: Oral prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 339773

Group type: EXPERIMENTAL
Intervention: Etomidate with polyethylene glycol as a solvent
Number of subjects: 0
Study: 30886334

Group type: EXPERIMENTAL
Intervention: Genetically-predicted triglycerides
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: Genetically-predicted log-transformed IL-6
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: Genetically-predicted log-transformed CRP
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: Family history of heart disease
Number of subjects: 367703

Group type: EXPERIMENTAL
Intervention: CHD genetic risk score
Number of subjects: 367703
Study: 31050233

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotic treatment
Number of subjects: 234

Group type: COMPARATOR
Intervention: Declined participation for LAI antipsychotic treatment
Number of subjects: 234

Group type: COMPARATOR
Intervention: Other reasons for declining participation
Number of subjects: 234
Study: 28720132

Group type: EXPERIMENTAL
Intervention: IND/GLY 110/50 μg q.d.
Number of subjects: 4389

Group type: COMPARATOR
Intervention: LABA + ICS
Number of subjects: 4389

Group type: COMPARATOR
Intervention: LABA or LAMA
Number of subjects: 4389
Study: 25890225

Group type: EXPERIMENTAL
Intervention: OpalSeal sealant application
Number of subjects: 36
Study: 24171685

Group type: COMPARATOR
Intervention: Above-elbow cast (AEC) for 6 weeks
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 3 weeks of AEC followed by 3 weeks of below-elbow cast (BEC)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 3 weeks of AEC followed by 3 weeks of BEC
Number of subjects: 127
Study: 21883109

Group type: EXPERIMENTAL
Intervention: Usual gait speed
Number of subjects: 217
Study: 19626471

Group type: EXPERIMENTAL
Intervention: Instrumented lumbar spinal fusion
Number of subjects: 94

Group type: COMPARATOR
Intervention: Non-instrumented lumbar spinal fusion
Number of subjects: 94
Study: 17450066

Group type: EXPERIMENTAL
Intervention: Gabapentin treatment
Number of subjects: 55

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 55
Study: 15870668

Group type: EXPERIMENTAL
Intervention: Glutamine supplement (0.6 g.kg ‐1 .d ‐1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no glutamine supplement)
Number of subjects: 20
Study: 11576569

Group type: EXPERIMENTAL
Intervention: Advance provision of emergency contraception (three courses of therapy) along with information
Number of subjects: 411

Group type: COMPARATOR
Intervention: Information only about emergency contraception
Number of subjects: 411
Study: 9561995

Group type: EXPERIMENTAL
Intervention: Accelerated care (admission to a nonintensive care unit and day 3 hospital discharge without noninvasive testing)
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Accelerated care
Number of subjects: 471
Study: 7880409

Group type: EXPERIMENTAL
Intervention: Ketorolac gel
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3066339

Group type: EXPERIMENTAL
Intervention: PGI2 infusion (4 to 12 hours daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31705683

Group type: EXPERIMENTAL
Intervention: Probiotic group receiving drops and lozenges containing L. reuteri (ATCC PTA 5289 & DSM 17938)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving placebo products
Number of subjects: 0
Study: 30301473

Group type: EXPERIMENTAL
Intervention: Exercise training (combined aerobic and resistance exercise)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no exercise)
Number of subjects: 32
Study: 28082098

Group type: EXPERIMENTAL
Intervention: 3D printing technology (3DP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 25554404

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg orally every other day for the first month and once daily thereafter, in addition to background therapy with ACEI or ARB.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo, in addition to background therapy with ACEI or ARB.
Number of subjects: 42
Study: 23675790

Group type: EXPERIMENTAL
Intervention: Wii Fit rehabilitation
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Traditional rehabilitation
Number of subjects: 28

Group type: COMPARATOR
Intervention: Wii Fit rehabilitation and Traditional rehabilitation
Number of subjects: 28
Study: 21597204

Group type: EXPERIMENTAL
Intervention: Right ventricular apical pacing (RVA)
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Right ventricular septal pacing (RVS)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 103
Study: 19862936

Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg twice a day)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 16760868

Group type: EXPERIMENTAL
Intervention: TEA+GA
Number of subjects: 80

Group type: COMPARATOR
Intervention: GA
Number of subjects: 80
Study: 15317711

Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse diode laser (810 nm)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional argon laser (514 nm)
Number of subjects: 16
Study: 10870744

Group type: EXPERIMENTAL
Intervention: NMDA-receptor antagonists (e.g., ketamine, dextromethorphan, memantine, amantadine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opioids (e.g., methadone, dextropropoxyphene, ketobemidone)
Number of subjects: 0
Study: 8894195

Group type: EXPERIMENTAL
Intervention: Compliance therapy
Number of subjects: 74
Study: 1814876

Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 18
Study: 6240470

Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cinoxacin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Oxolinic acid
Number of subjects: 125

Group type: COMPARATOR
Intervention: Nalidixic acid
Number of subjects: 125
Study: 28559003

Group type: EXPERIMENTAL
Intervention: PCV-13
Number of subjects: 155

Group type: COMPARATOR
Intervention: PPV-23
Number of subjects: 155

Group type: COMPARATOR
Intervention: PPV-23-pre-vaccinated
Number of subjects: 155
Study: 27871702

Group type: EXPERIMENTAL
Intervention: Reverse closing loop
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ladanyi spring
Number of subjects: 36

Group type: COMPARATOR
Intervention: Direct skeletal anchorage system
Number of subjects: 36

Group type: COMPARATOR
Intervention: Indirect skeletal anchorage system
Number of subjects: 36
Study: 25784663

Group type: EXPERIMENTAL
Intervention: Parental diabetes
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Parental hypertension
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Parental obesity (BMI >30 kg/m(2))
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Parental depressive symptoms
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Subclinical binge eating (BE) in parents
Number of subjects: 699
Study: 22961092

Group type: EXPERIMENTAL
Intervention: Cranberry juice (UR65), 125 mL once daily for 24 weeks
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo beverage, 125 mL once daily for 24 weeks
Number of subjects: 118
Study: 20200820

Group type: EXPERIMENTAL
Intervention: Back-pain specific information leaflet
Number of subjects: 174

Group type: COMPARATOR
Intervention: Leaflet without content regarding back pain (control)
Number of subjects: 174
Study: 17997364

Group type: EXPERIMENTAL
Intervention: PDA-based self-monitoring intervention
Number of subjects: 151
Study: 16011136

Group type: EXPERIMENTAL
Intervention: Pterygopalatine fossa infiltration with 2 mL of 2% lidocaine and 1:80,000 adrenalin
Number of subjects: 55

Group type: COMPARATOR
Intervention: Noninjected side
Number of subjects: 55
Study: 12970309

Group type: EXPERIMENTAL
Intervention: Estradiol valerate HRT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combined HRT with estradiol valerate and levonorgestrel
Number of subjects: 30
Study: 10090355

Group type: EXPERIMENTAL
Intervention: 15 g of alcohol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 30 g of alcohol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60 g of alcohol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0 g of alcohol (water)
Number of subjects: 40
Study: 7772781

Group type: EXPERIMENTAL
Intervention: Right ear occlusion
Number of subjects: 30

Group type: COMPARATOR
Intervention: Left ear occlusion
Number of subjects: 30
Study: 2148502

Group type: EXPERIMENTAL
Intervention: LBNP (Lower Body Negative Pressure) at -40 mmHg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: LBPP (Lower Body Positive Pressure)
Number of subjects: 17

Group type: COMPARATOR
Intervention: LBNP and LBPP in hypertensive patients with LVH
Number of subjects: 17
Study: 389338

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 51

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 51
Study: 31866081

Group type: EXPERIMENTAL
Intervention: DuraGraft
Number of subjects: 250

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 250
Study: 28514235

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg intravenous pretreatment)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (no ondansetron)
Number of subjects: 33
Study: 25901558

Group type: EXPERIMENTAL
Intervention: Low-dose CT (LDCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chest radiography
Number of subjects: 0
Study: 24237724

Group type: EXPERIMENTAL
Intervention: Aloe vera gel (n = 15 per category)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-aloe vera group (n = 15 per category)
Number of subjects: 60
Study: 21402559

Group type: EXPERIMENTAL
Intervention: Single stimulation with IM
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Triple stimulation with IM
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 19097758

Group type: EXPERIMENTAL
Intervention: Ertapenem 1 g intravenous dose
Number of subjects: 21
Study: 18175079

Group type: EXPERIMENTAL
Intervention: 3D-CTA as the primary diagnostic investigation
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Early surgical clipping of the aneurysm
Number of subjects: 38
Study: 15570830

Group type: EXPERIMENTAL
Intervention: Local anaesthetic (LA) group
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 96
Study: 11837512

Group type: EXPERIMENTAL
Intervention: Testosterone plus letrozole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone plus placebo
Number of subjects: 0
Study: 9551674

Group type: EXPERIMENTAL
Intervention: GM-CSF alone (65-250 microg/m2 three times weekly for 6 months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Interferon alone (3 mU three times weekly for 6 months)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Interferon + GM-CSF (3 mU + 250 microg/m2 three times weekly for 6 months)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: GM-CSF treatment
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Long-term sustained virologic response
Number of subjects: 71